Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesClinical Nephrology
You have accessRestricted Access

Two-Year Outcome of the ISKDC Regimen and Frequent-Relapsing Risk in Children with Idiopathic Nephrotic Syndrome

Koichi Nakanishi, Kazumoto Iijima, Kenji Ishikura, Hiroshi Hataya, Hitoshi Nakazato, Satoshi Sasaki, Masataka Honda, Norishige Yoshikawa and for the Japanese Study Group of Renal Disease in Children
CJASN May 2013, 8 (5) 756-762; DOI: https://doi.org/10.2215/CJN.09010912
Koichi Nakanishi
*Department of Pediatrics, Wakayama Medical University, Wakayama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazumoto Iijima
†Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenji Ishikura
‡Department of Nephrology, Tokyo Metropolitan Children’s Medical Center, Fuchu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Hataya
‡Department of Nephrology, Tokyo Metropolitan Children’s Medical Center, Fuchu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hitoshi Nakazato
§Department of Pediatrics, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoshi Sasaki
‖Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masataka Honda
‡Department of Nephrology, Tokyo Metropolitan Children’s Medical Center, Fuchu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norishige Yoshikawa
*Department of Pediatrics, Wakayama Medical University, Wakayama, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Summary

Background and objectives Early identification of frequently relapsing children with idiopathic nephrotic syndrome is desirable.

Design, setting, participants, & measurements The relapse status and clinical data of patients previously registered (January of 1993 to December of 2001) in a multicenter prospective study of the International Study of Kidney Disease in Children regimen were analyzed for risk of frequent relapsers over a 2-year follow-up period.

Results Of 166 children with nephrotic syndrome (113 boys and 53 girls; median age=5.1 years), 145 (87.3%, median age=5.5 years) children were steroid-sensitive, and 21 (12.7%, median age=2.9 years) children were steroid-resistant. Of 145 children with steroid-sensitive nephrotic syndrome, 32 (22.1%, median age=4.2 years) children experienced frequent relapses over 2 years. The time to initial response was significantly longer (10 versus 7 days, P<0.001, log-rank test) in the 32 frequent relapsers than in the 106 nonfrequent relapsers. The time from start of initial treatment to first relapse was significantly shorter (2.6 versus 6.1 months, P<0.001, log-rank test) in the 32 frequent relapsers than in the 57 infrequent relapsers. In a Cox regression model, the time to initial response ≥9 days and the duration from start of initial treatment to first relapse <6 months were significant predictors of frequent relapses (unadjusted and adjusted).

Conclusions Initial remission time ≥9 days and first relapse within 6 months were associated with frequent relapses. These findings may also be useful also in selecting potential frequent relapsers for clinical trials.

Introduction

The standard initial treatment for children with idiopathic nephrotic syndrome (NS), proposed by the International Study of Kidney Disease in Children (ISKDC), consists of an 8-week regimen of corticosteroids (1,2). Although more than 80% of children with idiopathic NS are steroid-sensitive (SS), about 60% of these patients experience relapses. Moreover, a considerable number have frequent relapses and develop corticosteroid toxicities after repeated treatments (1,2). Although some controlled studies (3–6) and a meta-analysis (7) have shown that long-course corticosteroid regimens result in a longer sustained remission of the disease than the ISKDC regimen, the most appropriate treatment of idiopathic NS has not been determined. There have been no recent large-scale reports of the outcome of the ISKDC regimen in patients with idiopathic NS. Early identification of frequently relapsing (FR) NS is desirable. We, therefore, assessed the 2-year outcomes and risks of FRNS after initial therapy based on the ISKDC regimen in children with idiopathic NS.

Materials and Methods

Patients

The study protocol was based on the Declaration of Helsinki and approved by the regional research ethics vetting boards (Wakayama Medical University #799). We analyzed data from children with idiopathic NS who had been in the control group (prednisolone alone) of a randomized control trial (RCT) of the Japanese Study Group of Renal Disease in Children testing Sairei-to, a Chinese herbal medicine, in patients with idiopathic NS to obtain basic data for new RCTs. Detailed information on these RCTs is available on the website http://www.wan.jp/jsrdc (Japanese version only available) and http://www.umin.ac.jp/ctr (UMIN000000747 and UMIN000005103). Between January of 1993 and December of 2001, children newly diagnosed with idiopathic NS at 46 hospitals in Japan were entered into the study. The criteria for NS were in accordance with ISKDC (8) and included (1) heavy proteinuria, ≥40 mg/h per meter2, (2) hypoalbuminemia, ≤2.5 g/dl, and (3) age at diagnosis, ≥1 and <16 years. In addition, none of these children had hematuria (<20 erythrocytes/high-power field), hypertension, hypocomplementemia, or renal insufficiency, and none had received immunosuppressive therapy. Patients/parents were instructed to dip the urine daily and record results.

Treatment Regimen

Initially, all patients received 2.0 mg/kg per day prednisolone (maximum of 80 mg) in three divided doses for 4 weeks followed by 1.3 mg/kg per 2 days in a single dose for 4 weeks. Treatment for each relapse consisted of 2.0 mg/kg per day prednisolone for 4 weeks followed by tapering to 2.0 mg/kg per 2 days in a single dose for 2 weeks, 1.0 mg/kg per 2 days for 2 weeks, and 0.5 mg/kg/2 days for 2 weeks. Prednisolone doses were calculated from the standard body weight per body length.

Clinical Definitions

Remission and relapse were defined in accordance with the guidelines of the ISKDC (8). Response was defined as a reduction in the rate of urinary protein excretion to <4 mg/h per meter2 (dipstick zero to trace with early-morning urine) for 3 consecutive days. SSNS was defined as a response during the initial 8-week prednisolone regimen, and steroid-resistant NS (SRNS) was defined as a failure to respond during the initial 8-week therapy. Relapse was defined as a reappearance of proteinuria≥40 mg/h per meter2 (dipstick≥2+ with early-morning urine) for 3 consecutive days. FRNS was defined as more than or equal to two relapses of NS within 6 months of the initial episode or more than or equal to four relapses within any 12-month period. Renal insufficiency was defined as an estimated GFR calculated using the Schwartz Equation (9) of <60 ml/min per 1.73 m2.

Statistical Analyses

All statistical analyses were performed using JMP9.0 software (SAS Institute Inc., Cary, NC). The clinical characteristics of patient groups were compared using Fisher’s exact test. Continuous variables were compared using the Wilcoxon test. Extended Fisher’s exact test and the Kruskal–Wallis test with posthoc Steel–Dwass test were used to compare differences among the three subpopulations of patients with SSNS. Time-course events of patients with SSNS were analyzed using the Kaplan–Meier method and the log-rank test. A Cox regression model was used to identify factors associated with the risk of FRNS (10). Factors related to FRNS were selected based on clinical importance. A two-tailed P value<0.05 was regarded as significant.

Results

Clinical Course, Onset Age, and Sex Ratio

A total of 166 children with idiopathic NS, 113 boys and 53 girls (2.1:1), satisfied the inclusion criteria; their conditions 2 years after the start of initial treatment are shown in Figure 1. Of these 166 children, 145 (87%) children, 98 boys and 47 girls (2.1:1), had SSNS, and 21 (13%) children, 15 boys and 6 girls (2.5:1), had SRNS. There was an overall male preponderance in both groups but no significant difference in sex ratio (P=0.81). Similarly, there were no differences in sex ratio when the SSNS group was subdivided into children with no relapse (31 boys and 18 girls), infrequent relapse (39 boys and 18 girls), and FR (23 boys and 9 girls) (P=0.89). The clinical characteristics of these patients are summarized in Table 1. Median onset age was similar in the SSNS and SRNS groups (P=0.18), but it differed significantly among the three SSNS subgroups (P=0.04), between FRs and nonrelapsers (P=0.03), and between FRs and non- and infrequent relapsers (P=0.05). There was no significant difference in median onset age between males and females in the SSNS and SRNS groups and three SSNS subgroups.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Status of 166 children with nephrotic syndrome 2 years from the start of initial treatment. Data are shown as median if applicable. N/A, not applicable; time for relapse, time from start of initial treatment to first relapse; time for remission, time from start of initial treatment to disappearance of proteinuria.

View this table:
  • View inline
  • View popup
Table 1.

Clinical data and status of 166 children with nephrotic syndrome

There was no significant difference in median of proteinuria, estimated GFR, total protein, albumin, and total cholesterol at onset among subgroups. Serum sodium was significant lower in the FR than the nonfrequent relapser group (P=0.008) (Table 1).

Detailed data of onset age are shown in Table 2. Approximately 50% of children with SSNS experienced onset from 2 to less than 6 years of age. The distributions of onset age differed significantly between the SSNS and SRNS groups (P=0.04). Children with SRNS were younger at onset, with 24% presenting with disease before 2 years of age. Two of five SRNS patients with onset age <2 years showed minor glomerular abnormality and FSGS. A renal biopsy was not done in one of five patients. There were no differences in the distributions of onset age between boys and girls in the SSNS (P=0.25) and SRNS (P=0.99) groups and in the entire cohort with NS (P=0.15). Of 145 patients in the SSNS group, 32 (22%) children, 23 boys and 9 girls (2.6:1), developed FRNS over the 2-year follow-up period, with 22 (69%) of these children being ≤5 years at onset.

View this table:
  • View inline
  • View popup
Table 2.

Subdivision of patients by age at the onset of idiopathic nephrotic syndrome

Kaplan–Meier analysis showed that 57%, 44%, 41%, and 39% of the patients in the SSNS group remained relapse-free at 6, 12, 18, and 24 months, respectively, from the start of initial treatment (Figure 2 and Table 3). All patients in the FRNS group had a first relapse within 6 months of the start of initial treatment; 24 (75%) of 32 patients with FRNS showed steroid-dependent NS during the 2-year study period.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Kaplan–Meier analysis of relapse-free ratio in children with steroid-sensitive nephrotic syndrome.

View this table:
  • View inline
  • View popup
Table 3.

Relapse-free rates after a standard or long regimen in patients with steroid-sensitive nephrotic syndrome

Time from the Start of Initial Treatment to Disappearance of Proteinuria in the SSNS Group

The median (25%–75%) times from the start of initial treatment to the disappearance of proteinuria in the SSNS group and its subgroups are shown in Table 1. This time was significantly longer in the FR (10 [8–13] days) than the nonrelapser (7 [5–8] days) and infrequent relapser (8 [7–9] days) subgroups (P<0.001 each). The time differed significantly between the FR and non-FR (nonrelapser and infrequent relapser) subgroups (10 [8–13] versus 7 [6–8] days, P<0.001). In contrast, the difference between the nonrelapser and infrequent relapser subgroups was not significant (P=0.07). Kaplan–Meier method and log-rank test also showed that the initial response time was significantly longer in the FR than the non-FR (Figure 3A). These findings suggest that the ease of proteinuria disappearance differed in the FRNS and non-FRNS groups. There were no significant differences between males and females in the SSNS group and its subgroups.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Initial remission ratio and relapse-free ratio in nephrotic syndrome. Kaplan–Meier analysis of time for initial remission (A) and time for first relapse (B). P values are from log-rank test. FRNS, frequent-relapsing nephrotic syndrome; IRNS, infrequent-relapsing nephrotic syndrome.

Time from the Start of Initial Treatment to First Relapse in Patients with SSNS

The median (25%–75%) time from the start of initial treatment to first relapse was significantly shorter in the FR than the infrequent relapser subgroups (2.6 [1.5–3.5] versus 6.1 [3.2–9.6] months, P<0.001) (Table 1). Kaplan–Meier method and log-rank test also showed that the first relapse was significantly earlier in the FR than the infrequent relapser (Figure 3B). There was no significant difference between males and females in either group.

Factors Associated with FRNS

Table 4 presents the results of Cox regression analyses of factors associated with FRNS. A time of initial response ≥9 days and time from start of initial treatment to first relapse <6 months were significant in both unadjusted (P<0.001 in both) and adjusted (P=0.004 and <0.001, respectively) analyses. The adjusted hazard ratio (HR) for an initial response time ≥9 days compared with <9 days was 3.09 (95% confidence interval [CI]=1.42–7.27). The adjusted HR for time from start of initial treatment to first relapse <6 months was 5.09×106 (95% CI=16.56–2.06×10184). Kaplan–Meier method and log-rank test also showed that initial remission time ≥9 days and first relapse within 6 months were associated with frequent relapsing (Figure 4). These findings suggest that an initial response within 9 days and an early first relapse, especially within 6 months, may be significant risk factors for the development of FRNS.

View this table:
  • View inline
  • View popup
Table 4.

Cox regression model of factors associated with frequently relapsing nephrotic syndrome at 2 years after initial therapy (n=138)

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Frequent relapse-free ratio stratified by times for initial remission and first relapse. Frequent relapse related with time to initial response (A) and time from start of initial treatment to first relapse (B). P values are from log-rank test.

Discussion

Prolonged initial steroid treatment for more than 3 months has been reported to decrease the risks of relapse in pediatric patients with SSNS (7,11,12). However, even with new corticosteroid regimens, 80%–90% of children with SSNS have relapses, with nearly 50% relapsing frequently (13). Therefore, the initial approach to the treatment of SSNS will likely vary considerably (14).

We have analyzed 2-year outcomes in children with primary NS after initial therapy based on the ISKDC regimen. Large-scale reports describing the outcomes of the ISKDC regimen in children with idiopathic NS have been published, but none have been published recently (2,15). Therefore, our study may provide valuable data on children with idiopathic NS, although they were from over 10 years ago.

Our results suggest that the incidence of FRNS in children with idiopathic NS was not as high as previously reported. We found that the incidence of FRNS was 19% among all children with NS (32 of 166) and 22% among children with SSNS (32 of 145) 2 years after initial treatment. In comparison, a previous study reported that the incidence of FRNS 6 months after initial treatment with prednisone was 28% among children with NS (102 of 363) and 31% among children with SSNS (102 of 334) (2). The Arbeitsgemeinschaft für Pädiatrische Nephrologie study reported that 12 of 37 (32%) patients with SSNS using the ISKDC regimen were FRNS 6 months after initial treatment (4), and a Cochrane meta-analysis found that 110 of 289 (38%) patients using the ISKDC regimen were FRNS (7), a significantly higher percentage than we observed (P<0.001, Fisher's exact test). Relatively small-scale studies from Japan included in the Cochrane analysis showing that the rates of FRNS were high, 43% (13 of 30) in 2000 (16) and 52% (15 of 29) in 1988 (3), suggesting that the differences in relapse rates were not caused by race or study period.

Of our 166 patients with NS, 21 (13%) patients had SRNS. SRNS generally depends on histology. Similarly, the ISKDC reported that 22% (103 of 471) had SRNS, with 7% (25 of 363) having minimal change (17). In addition, the sex ratios and onset age distributions among our patients were similar to those values reported previously (2,15,18).

The relapse-free ratio after initial treatment in our SSNS was intermediate between the standard and long Arbeitsgemeinschaft für Pädiatrische Nephrologie regimens and better than the ratio reported by the ISKDC (Table 3). These findings provide a rationale for reconsidering the ISKDC regimen.

We found that the times from the start of initial treatment to the disappearance of proteinuria differed significantly among our three SSNS subgroups, being significantly longer in FR than non-FR (10 versus 7 days) groups. A time of ≥9 days was significant for FRNS in both unadjusted and adjusted analyses. The adjusted HR for an initial response time ≥9 days compared with <9 days was 3.09 (95% CI=1.42–7.27, P=0.004). These findings suggest that the time from the start of initial treatment to the disappearance of proteinuria may predict whether a patient will develop FRNS. Patients with an initial response time ≥9 days should, therefore, be considered for more intensive treatments, such as a long course of corticosteroids. This time cutoff may also be useful for selecting potential FRs for clinical trials. Interestingly, an initial remission time ≥9 days (odds ratio=3.00, 95% CI=1.20–7.90, P=0.02, n=123) was previously shown to be a significant predictor of steroid dependency in a logistic model (19). Another study, however, reported no correlation between time to initial response and frequency of relapse in 218 SSNS patients who showed minimal change during the 2 years after initial response (8). The reason for these discrepancies is unclear, although they may have been because of differences in the ethnic/racial characteristics of the included patients.

Both unadjusted and adjusted analyses showed that the time from start of initial treatment to first relapse was a significant predictor of FRNS. The adjusted odds ratio for the time from initiation of treatment to first relapse <6 months was 5.09×106 (95% CI=16.56–2.06×10184, P<0.001). These findings suggest that patients who relapse within 6 months after initial remission be considered for more intensive treatment. Based on this finding, an RCT has been designed to examine the efficacy and safety of mizoribine, one of immunosuppressants, to prevent FRNS (UMIN000005103).

A limitation may be the possibility of influence of difference in treatment for each relapse between the original ISKDC regimen and our regimen, although one of the ISKDC RCTs showed that there was no significant difference in the number of relapses during the follow-up period of 6 months between the original ISKDC regimen and the prolonged regimen similar to our regimen (20). Generally, renal biopsies are not indicated at onset when patients fulfill the inclusion criteria of this study. Therefore, renal biopsies were not required for the study. Another limitation is that our study did not include a validation cohort. Therefore, data in the current study should be validated in a separate cohort.

Although we did not examine biochemical parameters such as lipoprotein(a), there is a report suggesting the predictive value of it in nephrotic status (21).

In conclusion, despite this study being prospective and observational in nature rather than a controlled study, our findings suggest the validity of the ISKDC regimen in the treatment of patients with idiopathic NS. Our data also indicated that an initial remission time ≥9 days and first relapse within 6 months were significant risks for the development of FRNS. These findings may also be useful in selecting potential FRs for clinical trials.

Disclosures

None.

Acknowledgments

The authors thank the patients and Drs. Akioka Y (Tokyo), Araki Y (Hokkaido), Awazu M (Tokyo), Baba M (Kanagawa), Furuse A (Kumamoto), Fujinaga S (Saitama), Goto M (Tokyo), Hamada R (Tokyo), Hamahira K (Hyogo), Hamasaki Y (Tokyo), Harada T (Kanagawa), Hatae K (Fukuoka), Hattori M (Tokyo), Hattori S (Kumamoto), Hayashida S (Kumamoto), Higashida K (Yamanashi), Hiramatsu M (Oita), Hiramoto R (Chiba), Igarashi T (Tokyo), Ikeda M (Tokyo), Ikeda T (Kumamoto), Ishihara Y (Kanagawa), Ito S (Kanagawa), Kagami S (Tokushima), Kaku Y (Fukuoka), Kameda A (Hyogo), Kamei K (Tokyo), Kamezaki K (Fukuoka), Kamimaki I (Tochigi), Kamitsuji H (Nara), Kitagawa K (Hyogo), Kobayashi Y (Tochigi), Kodama S (Kagoshima), Konomoto T (Miyazaki), Kosaka T (Tokyo), Maeda E (Gunma), Matsuyama T (Tokyo), Minato T (Hyogo), Mishiku Y (Kanagawa), Miyamoto H (Hyogo), Morita M (Tochigi), Nakanishi N (Osaka), Niimura F (Kanagawa), Nishino M (Osaka), Nozu K (Hyogo), Ochiai R (Tokyo), Ota K (Hyogo), Otsuka Y (Saga), Owada Y (Tochigi), Sako M (Tokyo), Sato T (Saga), So H (Kagoshima), Suehiro F (Hyogo), Suzuki T (Tokyo), Tamura K (Ibaraki), Tanaka R (Hyogo), Tanaka Y (Tokyo), Tsuchida S (Akita), Ushijima T (Kumamoto), Wakaki H (Tokyo), Yamaoka K (Osaka), Yan K (Tokyo), Yoshidome K (Kagoshima), and Yoshiya K (Hyogo) of the Japanese Study Group of Renal Disease in Children for their contributions.

This study was supported in part by the Kidney Foundation, Japan.

Parts of this study were presented at the 37th Annual Meeting of the American Society of Nephrology, October 30, 2004, St. Louis, Missouri, and published in abstract form (Nakanishi et al., J Am Soc Nephrol, 15: 358A, 2004).

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Received September 3, 2012.
  • Accepted December 21, 2012.
  • Copyright © 2013 by the American Society of Nephrology

References

  1. ↵
    1. van Husen M,
    2. Kemper MJ
    : New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 26: 881–892, 2011pmid:21229269
    OpenUrlCrossRefPubMed
  2. ↵
    1. Tarshish P,
    2. Tobin JN,
    3. Bernstein J,
    4. Edelmann CM Jr.
    : Prognostic significance of the early course of minimal change nephrotic syndrome: Report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8: 769–776, 1997pmid:9176846
    OpenUrlAbstract
  3. ↵
    1. Ueda N,
    2. Chihara M,
    3. Kawaguchi S,
    4. Niinomi Y,
    5. Nonoda T,
    6. Matsumoto J,
    7. Ohnishi M,
    8. Yasaki T
    : Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. J Pediatr 112: 122–126, 1988pmid:3335948
    OpenUrlCrossRefPubMed
  4. ↵
    1. Ehrich JH,
    2. Brodehl J
    : Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Eur J Pediatr 152: 357–361, 1993pmid:8482290
    OpenUrlCrossRefPubMed
    1. Ksiazek J,
    2. Wyszyńska T
    : Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Acta Paediatr 84: 889–893, 1995pmid:7488812
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bagga A,
    2. Hari P,
    3. Srivastava RN
    : Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome. Pediatr Nephrol 13: 824–827, 1999pmid:10603129
    OpenUrlCrossRefPubMed
  6. ↵
    1. Hodson EM,
    2. Willis NS,
    3. Craig JC
    : Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 17: CD001533, 2007
    OpenUrl
  7. ↵
    1. International Study of Kidney Disease in Children
    : Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children. J Pediatr 101: 514–518, 1982pmid:7119952
    OpenUrlCrossRefPubMed
  8. ↵
    1. Schwartz GJ,
    2. Haycock GB,
    3. Edelmann CM Jr.,
    4. Spitzer A
    : A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58: 259–263, 1976pmid:951142
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Cox DR,
    2. Oakes D
    : Analysis of Survival Data, London, Chapman & Hall, 1984
  10. ↵
    1. Hodson EM,
    2. Alexander SI
    : Evaluation and management of steroid-sensitive nephrotic syndrome. Curr Opin Pediatr 20: 145–150, 2008pmid:18332709
    OpenUrlCrossRefPubMed
  11. ↵
    1. Hodson EM,
    2. Craig JC,
    3. Willis NS
    : Evidence-based management of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 20: 1523–1530, 2005pmid:15968558
    OpenUrlCrossRefPubMed
  12. ↵
    1. Hodson EM,
    2. Willis NS,
    3. Craig JC
    : Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev 23: CD002290, 2008pmid:18254005
    OpenUrlPubMed
  13. ↵
    1. MacHardy N,
    2. Miles PV,
    3. Massengill SF,
    4. Smoyer WE,
    5. Mahan JD,
    6. Greenbaum L,
    7. Massie S,
    8. Yao L,
    9. Nagaraj S,
    10. Lin JJ,
    11. Wigfall D,
    12. Trachtman H,
    13. Hu Y,
    14. Gipson DS
    : Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol 24: 2193–2201, 2009pmid:19672630
    OpenUrlCrossRefPubMed
  14. ↵
    1. White RH,
    2. Glasgow EF,
    3. Mills RJ
    : Clinicopathological study of nephrotic syndrome in childhood. Lancet 1: 1353–1359, 1970pmid:4194123
    OpenUrlCrossRefPubMed
  15. ↵
    1. Hiraoka M,
    2. Tsukahara H,
    3. Haruki S,
    4. Hayashi S,
    5. Takeda N,
    6. Miyagawa K,
    7. Okuhara K,
    8. Suehiro F,
    9. Ohshima Y,
    10. Mayumi M,
    11. The West Japan Cooperative Study of Kidney Disease in Children
    : Older boys benefit from higher initial prednisolone therapy for nephrotic syndrome. Kidney Int 58: 1247–1252, 2000pmid:10972687
    OpenUrlCrossRefPubMed
  16. ↵
    1. International Study of Kidney Disease in Children
    : The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 98: 561–564, 1981pmid:7205481
    OpenUrlCrossRefPubMed
  17. ↵
    1. International Study of Kidney Disease in Children
    : Nephrotic syndrome in children: Prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 13: 159–165, 1978pmid:713276
    OpenUrlCrossRefPubMed
  18. ↵
    1. Yap HK,
    2. Han EJ,
    3. Heng CK,
    4. Gong WK
    : Risk factors for steroid dependency in children with idiopathic nephrotic syndrome. Pediatr Nephrol 16: 1049–1052, 2001pmid:11793098
    OpenUrlCrossRefPubMed
  19. ↵
    1. International Study of Kidney Disease in Children
    : Nephrotic syndrome in children: A randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the International Study of Kidney Disease in Children. J Pediatr 95: 239–243, 1979pmid:109598
    OpenUrlCrossRefPubMed
  20. ↵
    1. Kawasaki Y,
    2. Suzuki J,
    3. Nozawa R,
    4. Suzuki S,
    5. Suzuki H
    : Prediction of relapse by plasma lipoprotein(a) concentration in children with steroid-sensitive nephrotic syndrome. Nephron 92: 807–811, 2002pmid:12399624
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 8 (5)
Clinical Journal of the American Society of Nephrology
Vol. 8, Issue 5
May 07, 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Two-Year Outcome of the ISKDC Regimen and Frequent-Relapsing Risk in Children with Idiopathic Nephrotic Syndrome
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Two-Year Outcome of the ISKDC Regimen and Frequent-Relapsing Risk in Children with Idiopathic Nephrotic Syndrome
Koichi Nakanishi, Kazumoto Iijima, Kenji Ishikura, Hiroshi Hataya, Hitoshi Nakazato, Satoshi Sasaki, Masataka Honda, Norishige Yoshikawa, for the Japanese Study Group of Renal Disease in Children
CJASN May 2013, 8 (5) 756-762; DOI: 10.2215/CJN.09010912

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Two-Year Outcome of the ISKDC Regimen and Frequent-Relapsing Risk in Children with Idiopathic Nephrotic Syndrome
Koichi Nakanishi, Kazumoto Iijima, Kenji Ishikura, Hiroshi Hataya, Hitoshi Nakazato, Satoshi Sasaki, Masataka Honda, Norishige Yoshikawa, for the Japanese Study Group of Renal Disease in Children
CJASN May 2013, 8 (5) 756-762; DOI: 10.2215/CJN.09010912
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Summary
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Association of Polypharmacy with Kidney Disease Progression in Adults with CKD
  • The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function
  • Collectin11 and Complement Activation in IgA Nephropathy
Show more Original Articles

Clinical Nephrology

  • Provider Perspectives and Clinical Outcomes with Inpatient Telenephrology
  • Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial
  • Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure
Show more Clinical Nephrology

Cited By...

  • Incidence and Relapse of Idiopathic Nephrotic Syndrome: Meta-analysis
  • Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial
  • The Effect of a Gluten-Free Diet in Children With Difficult-to-Manage Nephrotic Syndrome
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire